Jaguar Health开始研究Canalevia-CA1,旨在更广泛地批准在狗中治疗腹泻。 Jaguar Health begins study on Canalevia-CA1, aiming for broader approval to treat diarrhea in dogs.

Jaguar Health已开始对Canalevia-CA1进行实地研究,该药物经批准用于治疗狗体内因化疗引起的腹泻。 Jaguar Health has started a field study for Canalevia-CA1, a drug approved for treating chemotherapy-induced diarrhea in dogs. 该公司的目的是获得美国和欧盟批准在狗中进行一般腹泻治疗的药物。 The company aims to get the drug approved for general diarrhea treatment in dogs both in the U.S. and the EU. Canalevia 含有氯氟化碳,通过对胃肠道中的氯化物管道进行调控,减少腹泻。 Canalevia contains crofelemer, which reduces diarrhea by modulating chloride channels in the gastrointestinal tract. Jaguar公司正在寻求建立伙伴关系,推动该药物在全球的核准和商业化。 Jaguar is seeking partnerships to advance the drug's approval and commercialization globally.